Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.

There was a trend for increased post-operative volumes and a higher proportion of IDH wild-type tumors in our expansion cohort compared to our initial neoadjuvant cohort which may have impacted survival, though they did not reach statistical significance.

also in 111,027 other papers